GRACEcast - Discussions with the Global Resource for Advancing Cancer Education
By cancerGRACE
Listen to a podcast, please open Podcast Republic app. Available on Google Play Store and Apple App Store.
Image by cancerGRACE
Category: Medicine
Open in Apple Podcasts
Open RSS feed
Open Website
Rate for this podcast
Subscribers: 0
Reviews: 0
Episodes: 204
Description
In this podcast series, the Global Resource for Advancing Cancer Education (GRACE) works to bring professionals together with patients and caregivers to work in partnership.
We interview patients, advocates and healthcare professionals to provide the most updated information for our community and to highlight important issues facing those dealing with a cancer diagnosis.
For more information visit www.cancerGRACE.org. To join the conversation, visit https://cancergrace.org/forums
We interview patients, advocates and healthcare professionals to provide the most updated information for our community and to highlight important issues facing those dealing with a cancer diagnosis.
For more information visit www.cancerGRACE.org. To join the conversation, visit https://cancergrace.org/forums
| Episode | Date |
|---|---|
|
Efficacy of Epcoritamab and Glofitamab in Diffuse Large B-Cell Lymphoma
|
May 03, 2024 |
|
Barriers to Biomarker Testing: Cost and Insurance
|
Apr 27, 2024 |
|
Barriers to Biomarker Testing: Ordering Tests
|
Apr 20, 2024 |
|
The Adaura Trial: The Effect on EGFR+ Treatment
|
Apr 15, 2024 |
|
Biomarker Driven Therapy for NSCLC
|
Apr 13, 2024 |
|
Current Recommendations and Best Practices for Biomarker Testing
|
Apr 11, 2024 |
|
The Importance of Biomarker Testing: What is Liquid Biopsy?
|
Apr 09, 2024 |
|
Biomarkers in NSCLC
|
Apr 09, 2024 |
|
Key Points from the Adaura Trial: Osimertinib
|
Nov 30, 2023 |
|
Biomarkers in NSCLC
|
Nov 23, 2023 |
|
The Importance of Biomarker Testing: What is Liquid Biopsy?
|
Nov 16, 2023 |
|
Barriers to Biomarker Testing: Cost and Insurance
|
Nov 10, 2023 |
|
Neoadjuvant Treatment for Patients with NSCLC
|
Oct 27, 2023 |
|
The Alina Trial for ALK+ NSCLC
|
Oct 21, 2023 |
|
Local Therapy for Limited Metastatic NSCLC
|
Oct 17, 2023 |
|
Immunotherapy for Patients with Resectable NSCLC and a Driver Mutation
|
Oct 10, 2023 |
|
Treatment Options for Patients with Locally Advanced Unresectable NSCLC
|
Oct 03, 2023 |
|
Local Therapy for NSCLC Patients After Frontline Therapy
|
Sep 27, 2023 |
|
The Role of the Patient as Advocate
|
Sep 24, 2023 |
|
Targeted Therapy Before Surgery in Patients with Resectable NSCLC and Driver Mutation
|
Sep 20, 2023 |
|
Local Therapy for Patients with Oligoprogressive NSCLC
|
Sep 15, 2023 |
|
The Future of Local Therapy in Lung Cancer
|
Sep 14, 2023 |
|
Adding to Targeted Therapy: Current Statistics and Biology
|
Sep 14, 2023 |
|
The Importance of Prostate Cancer Screening
|
Sep 01, 2023 |
|
सामान्य परामर्श मुद्दे (Common Consultation Issues)
|
Aug 30, 2023 |
|
पुरुषत्वीकरण चिकित्सा और द्वितीय एरिथ्रोसाइटोसिस (Masculinizing Therapy and Secondary Erythrocytosis)
|
Aug 23, 2023 |
|
सिकल सेल रोग और जेंडर अफर्मिंग हार्मोन थेरेपी (Sickle Cell Disease and Gender Affirming Hormone Therapy)
|
Aug 16, 2023 |
|
फेमिनाइजिंग थेरेपी और थ्रोम्बोसिस (Feminizing Therapy and Thrombosis)
|
Aug 09, 2023 |
|
भारत में ट्रांसजेंडर मुद्दे (Transgender Issues in India)
|
Aug 04, 2023 |
|
Neoadjuvant Therapy in Melanoma: Does It Give a Better Immune Response?
|
Jun 07, 2023 |
|
Neoadjuvant Therapy for Melanoma
|
Jun 02, 2023 |
|
Adjuvant Therapy for Melanoma
|
May 29, 2023 |
|
Adjuvant Therapy in Stage 3 and 4 Melanoma
|
May 26, 2023 |
|
Patient Selection for First Line Therapy in Stage 4 Melanoma
|
May 22, 2023 |
|
Neoadjuvant Therapy in Melanoma: The PRADO Trial
|
May 19, 2023 |
|
Major Advances in Uveal Melanoma
|
May 15, 2023 |
|
Clinical Trials in Melanoma
|
May 14, 2023 |
|
Incidence Trends in Melanoma
|
May 13, 2023 |
|
Side Effects of Immunotherapy in Melanoma
|
May 11, 2023 |
|
Treatment for Metastatic Melanoma
|
May 01, 2023 |
|
BRAF Mutated Melanoma
|
Mar 06, 2023 |
|
Melanoma and Current Treatment Options
|
Feb 28, 2023 |
|
Emerging Types of CAR T-Cell Therapy
|
Feb 22, 2023 |
|
CAR T-Cell Therapy Side Effects
|
Feb 15, 2023 |
|
CAR T-Cell Therapy for Patients with Relapsed Diffuse Large B-Cell Lymphoma
|
Feb 09, 2023 |
|
Treatment Options for Relapsed Diffuse Large B-Cell Lymphoma
|
Feb 08, 2023 |
|
Emerging Immunotherapy Treatments for B-Cell Non-Hodgkin's Lymphoma: Bispecific Antibodies
|
Feb 08, 2023 |
|
Emerging Immunotherapy Treatments for B-Cell Non-Hodgkin's Lymphoma: CAR-T Cells
|
Feb 08, 2023 |
|
Covid-19 and Lung Cancer Screening
|
Feb 08, 2023 |
|
Who Should Receive Lung Cancer Screening?
|
Jan 05, 2023 |
|
What is Involved in Lung Cancer Screening?
|
Dec 28, 2022 |
|
Timelines in Cancer Care
|
Dec 21, 2022 |
|
Efficiency and Effectiveness of Cancer Care
|
Dec 14, 2022 |
|
Is My Lung Cancer Mutation Genetic?
|
Dec 07, 2022 |
|
The Prevalence of Breast Cancer and Tools for Early Detection
|
Nov 30, 2022 |
|
Types of Imaging Tests for Breast Cancer
|
Nov 23, 2022 |
|
Anomalies on Breast Cancer Imaging: Next Steps
|
Nov 16, 2022 |
|
The Importance of Patient Centered Care
|
Nov 10, 2022 |
|
Symptoms of Breast Cancer
|
Nov 09, 2022 |
|
Key Players for Lung Cancer Program Success
|
Nov 08, 2022 |
|
Treatment After Diagnosis of Breast Cancer
|
Nov 02, 2022 |
|
Goals of Lung Cancer Advocacy
|
Nov 01, 2022 |
|
The Importance of Breast Cancer Screening
|
Oct 27, 2022 |
|
Prevalence of EGFR-Mutant NSCLC in Asian and Caucasian Communities
|
Oct 20, 2022 |
|
Advancements of Targeted Therapy for EGFR Mutations in NSCLC
|
Oct 12, 2022 |
|
Choosing First Line Therapy in EGFR Mutations
|
Oct 04, 2022 |
|
Osimertinib and the FLAURA Trial
|
Sep 29, 2022 |
|
Preferential Timing for Molecular Testing in NSCLC
|
Sep 21, 2022 |
|
Immunotherapy Before Surgery in NSCLC
|
Sep 14, 2022 |
|
Immunotherapy for Patients with Driver Mutation
|
Sep 07, 2022 |
|
Immunotherapy for Oligometastatic Disease
|
Sep 01, 2022 |
|
Gene Mutations in NSCLC
|
Aug 30, 2022 |
|
Testing Methodology for NSCLC: Immunohistochemistry
|
Aug 28, 2022 |
|
Testing Methodology for NSCLC: FISH
|
Aug 27, 2022 |
|
Testing Methodology for NSCLC: PCR Testing
|
Aug 26, 2022 |
|
Testing Methodology for NSCLC: Next Generation Sequencing (NGS)
|
Aug 25, 2022 |
|
Circulating Tumor DNA in NSCLC
|
Aug 25, 2022 |
|
Mesothelioma Updates, Episode 6: Peritoneal Disease
|
Jul 06, 2022 |
|
Mesothelioma Updates, Episode 5: Future Approaches
|
Jun 28, 2022 |
|
Mesothelioma Updates, Episode 4: Chemo and Immunotherapy
|
Jun 22, 2022 |
|
Mesothelioma Updates, Episode 3: Surgical Options
|
Jun 14, 2022 |
|
Mesothelioma Updates, Episode 2: Diagnosis and Staging
|
Jun 07, 2022 |
|
Mesothelioma Updates, Episode 1: Epidemiology
|
Jun 01, 2022 |
|
Targeted Therapy Forum, Episode 10: Cost and Treatment Options
|
May 25, 2022 |
|
Targeted Therapies Forum, Episode 9: Telemedicine and Cancer
|
May 18, 2022 |
|
Targeted Therapies Forum, Episode 8: Detecting TKI Resistance with Liquid Biopsy
|
Apr 20, 2022 |
|
Targeted Therapies Forum, Episode 7: Pleural Fluid or Blood Biopsy?
|
Apr 13, 2022 |
|
Targeted Therapies Forum, Episode 6: Coverage, Cost, and Standard of Care for Biopsy
|
Apr 06, 2022 |
|
Targeted Therapies Forum, Episode 5: Circulating Tumor DNA
|
Apr 01, 2022 |
|
Targeted Therapies Forum, Episode 4: Diagnosis and Testing Relevance
|
Mar 28, 2022 |
|
Targeted Therapies Forum, Episode 2: The Complimentary Use of Liquid and Tissue Biopsies
|
Mar 19, 2022 |
|
Targeted Therapies, Episode 3: Anxiety and Symptom Burden
|
Mar 15, 2022 |
|
Targeted Therapies Forum 2021, Episode 1: Liquid and Tissue Biopsies in Acquired Resistance
|
Mar 04, 2022 |
|
Melanoma Updates - Molecular Profiling and Driver Mutations in Melanoma Treatment
|
Feb 04, 2022 |
|
Melanoma Updates - The Importance of Screening for Skin Cancers
|
Feb 01, 2022 |
|
Melanoma Updates -- Leptomeningeal Disease/ Brain Mets in Melanoma
|
Feb 01, 2022 |
|
Melanoma Updates The Role of Neoadjuvant Treatment in Melanoma Care
|
Jan 24, 2022 |
|
Melanoma Updates Treatment Options for Metastatic Melanoma
|
Jan 24, 2022 |
|
Melanoma Updates Potential Toxicities Associated with Immunotherapy in the Treatment of Melanoma
|
Jan 24, 2022 |
|
Brain Metastases in Breast Cancer Risks of Developing Brain Metastasis in Breast Cancer
|
Jan 24, 2022 |
|
Brain Metastases in Breast Cancer Treatment Options and Efficacy
|
Jan 24, 2022 |
|
Telemedicine vs. In-Person Treatment: What Have we Learned?
|
Jan 24, 2022 |
|
Is There a Place for Telemedicine in Oncology?
|
Jan 24, 2022 |
|
Opening Up and Masking: Is it Safe?
|
Jan 24, 2022 |
|
The Oncologist's Role: Educating Patients During a Pandemic
|
Jan 24, 2022 |
|
The Variable Acceptance of the Covid Vaccine
|
Jan 24, 2022 |
|
Brain Metastases in Breast Cancer Treatment Options for Breast Cancer Patients who Relapse with Only CNS Metastases
|
Jan 23, 2022 |
|
Brain Metastases in Breast Cancer, Prognosis and Impact on Survival
|
Jan 22, 2022 |
|
Melanoma Updates - Adjuvant Treatment Options for Melanoma
|
Jan 21, 2022 |
|
Metastatic Triple Negative Breast Cancer Immunotherapy Treatment Options and Potential Side Effects
|
Jan 21, 2022 |
|
Recent Data and Developments in Palliative Head and Neck Cancer Treatments
|
Jan 20, 2022 |
|
Palliative Care and Studies for Incurable Head and Neck Cancers
|
Jan 20, 2022 |
|
HPV and Head and Neck Cancers
|
Jan 20, 2022 |
|
Curative Modalities and Immunotherapy for Head and Neck Cancers
|
Jan 20, 2022 |
|
Metastatic Triple Negative Breast Cancer Antibody-Drug Conjugate Treatment Options
|
Jan 20, 2022 |
|
Metastatic Triple Negative Breast Cancer Targeted Therapy Treatment Options and Potential Side Effects
|
Jan 19, 2022 |
|
Surgical Management in Breast Cancer Body Image and Reconstruction Surgery
|
Jan 18, 2022 |
|
Surgical Management in Breast Cancer What to Expect During Surgery
|
Jan 17, 2022 |
|
Surgical Management in Breast Cancer What to Expect After Surgery
|
Jan 16, 2022 |
|
Surgical Management in Breast Cancer Long Term Outcomes - Breast Conserving Therapy vs. Mastectomy
|
Jan 16, 2022 |
|
Surgical Management in Breast Cancer The Role of Different Types of Surgery and the Management of Patients with Breast Cancer
|
Jan 15, 2022 |
|
Surgical Management in Breast Cancer Prophylactic Mastectomy on the Opposite Breast
|
Jan 14, 2022 |
|
Brain Metastases in Breast Cancer Signs, Symptoms, Screening and Treatment for Brain Metastases in Breast Cancer
|
Jan 14, 2022 |
|
Surgical Management in Breast Cancer Surgical Removal of Lymph Nodes - Sentinel Lymph Node Biopsy vs. Axillary Lymph Node Dissection (ALND)
|
Jan 14, 2022 |
|
GraceCAST 2021 Spanish COVID Panel-Vacunas contra el COVID en pacientes con cancer
|
Sep 25, 2021 |
|
GraceCAST 2021 Spanish COVID Panel- Usos de la Telemedicina para pacientes con cancer
|
Sep 23, 2021 |
|
GraceCAST Spanish COVID Panel-Impacto de la Covid-19 en la atención de pacientes con cáncer
|
Sep 22, 2021 |
|
GraceCAST Podcast-2021 English Q1 COVID Panel- COVID-19 Variants and the Challenge for Cancer Care
|
Sep 21, 2021 |
|
GraceCAST Podcast-2021 English Q1 COVID Panel- What Patients Should Expect Post COVID-19 Vaccination
|
Sep 21, 2021 |
|
GraceCAST Podcast-2021 English Q1 COVID Panel- The Continued Use of Telemedicine in Cancer Treatment
|
Sep 21, 2021 |
|
GraceCAST Podcast-2021 English Q1 COVID Panel- Is the COVID-19 Vaccine Safe For Cancer Patients
|
Sep 21, 2021 |
|
GraceCAST 2021 COVID Panel - Changes and Challenges of Consistent Cancer Care During the Pandemic
|
Jul 03, 2021 |
|
GraceCAST 2021 COVID Panel - COVID 19 Pandemic and the Impact on Cancer Care
|
Jul 01, 2021 |
|
GRACECast - Are there alternatives to radiation for patients with brain metastases
|
Jun 16, 2021 |
|
GRACECast - What is the optimal treatment for patients with advanced NSCLC and a BRAF-V600E mutation
|
Jun 09, 2021 |
|
GRACECast - What is tumor mutational burden TMB and could it be helpful in lung cancer management today
|
Jun 02, 2021 |
|
GRACECast - Treatment Options for Metastatic NSCLC
|
May 26, 2021 |
|
GRACEcast - Are there treatment options for patients with HER-2 NSCLC
|
May 20, 2021 |
|
PODCAST-GRACEcast- Dr. Sandip Patel- Emerging Molecular Targets in NSCLC- KRAS
|
May 12, 2021 |
|
GRACEcast- Dr. Sandip Patel- Emerging Molecular Targets in NSCLC- EGFR Exon 20
|
May 05, 2021 |
|
GRACEcast- ASCO LUNG 2020- Enhertu and the Potential for Treatment of HER2 Positive NSCLC
|
Apr 28, 2021 |
|
GRACEcast- ASCO LUNG 2020- The SINDAS Trial - The Addition of SBRT to a Systemic EGFR inhibitor TKI in EGFR positive NSCLC
|
Apr 21, 2021 |
|
GRACEcast- ASCO LUNG 2020- New Potential Treatments for MET and RET Positive NSCLC Capmatinib-Tabrecta and BLU-667-Pralsetinib
|
Apr 14, 2021 |
|
GRACECast - LCVL Can EGFR inhibitor therapy treat and prevent brain metastases
|
Mar 31, 2021 |
|
GRACECast - LCVL- What are the options after a patient with an ALK-positive advanced NSCLC develops resistance on Alecensa-alectinib
|
Mar 24, 2021 |
|
GRACECast - LCVL - Can immunotherapy help frail patients with advanced NSCLC
|
Mar 17, 2021 |
|
GRACECast - LCVL What is the role of immunotherapy for unresectable Stage 3 NSCLC today
|
Mar 12, 2021 |
|
GRACECast - LCVL - H. Jack West MD - Can ALK inhibitors treat and prevent brain metastases
|
Mar 12, 2021 |
|
GRACECast - LCVL - Can blood-based mutation-testing help shape treatment decisions for advanced NSCLC
|
Feb 24, 2021 |
|
GRACECast - LCVL - Consolidation immunotherapy after chemo-radiation for stage 3 unresectable NSCLC
|
Feb 17, 2021 |
|
GRACECast - LCVL -Can local therapies improve outcomes for stage IV NSCLC?
|
Feb 16, 2021 |
|
GRACECast - LCVL - Could pre-operative immunotherapy improve outcomes in early stage NSCLC
|
Feb 03, 2021 |
|
GRACECast - LCVL - Leading treatment options for patients with low or negative tumor PD-L1 expression and advanced nonsquamous NSCLC today
|
Jan 27, 2021 |
|
GRACECast - LCVL - Can patients with an EGFR mutation-positive advanced NSCLC benefit from immunotherapy
|
Jan 20, 2021 |
|
GRACEcast - LCVL - What are the leading first line treatment options for advanced NSCLC harboring an ALK rearrangement today
|
Dec 30, 2020 |
|
GRACEcast - LCVL - Can immunotherapy help patients with small cell lung cancer
|
Dec 23, 2020 |
|
GRACEcast - LCVL - Leading treatment options for patients with low or negative tumor PD-L1 expression and advanced squamous NSCLC today
|
Dec 16, 2020 |
|
GRACEcast - LCVL - What is the best first line treatment for patients with advanced EGFR mutation-positive NSCLC today
|
Dec 09, 2020 |
|
GRACEcast - LCVL - Which patients with advanced NSCLC are good candidates for first line immunotherapy alone today
|
Dec 02, 2020 |
|
GRACEcast - LCVL What is the current standard of care for patients with extensive stage small cell lung cancer
|
Nov 25, 2020 |
|
GRACEcast - Treatment options for patients with NSCLC and high tumor PD-L1 expression
|
Nov 18, 2020 |
|
GRACEcast - Treatment options for patients with advanced NSCLC and a HER2- ERBB2 mutation
|
Nov 11, 2020 |
|
GRACECast - Does immunotherapy have activity in malignant pleural mesothelioma
|
Nov 04, 2020 |
|
GRACEcast - Leading Treatment Options for Patients with Negative Tumor PD-L1 NSCLC with Dr. Stephen Liu
|
Oct 28, 2020 |
|
GRACEcast - Immunotherapy for Small Cell Lung Cancer with Dr. Stephen Liu
|
Oct 21, 2020 |
|
GRACEcast - Emerging Molecular Targets in NSCLC- RET Fusions with Dr. Josh Bauml
|
Oct 14, 2020 |
|
GRACEcast - Emerging Molecular Targets in NSCLC- MET with Dr. Josh Bauml
|
Oct 07, 2020 |
|
GRACEcast 2020 - Updates in Small Cell Lung Cancer with Dr. Jared Weiss
|
Sep 30, 2020 |
|
GRACEcast 2020 - New TKIs for Stage IV Non Small Cell Lung Cancer Mutations with Dr. Jared Weiss
|
Sep 23, 2020 |
|
GRACEcast 2020- Treatment Option Explored in the ADAURA Trial with Dr. Jared Weiss
|
Sep 21, 2020 |
|
Case Based Panel Discussion - EGFR Mutation Patient Progression and Next Steps
|
Sep 09, 2020 |
|
Case Based Panel Discussion - EGFR Mutation and High PDL1 - What is the Role of Immunotherapy in Treatment Decisions
|
Sep 02, 2020 |
|
Case Based Panel Discussion - EGFR Mutation with MET Amplification Treatment Decisions and the Importance of the Level of MET Amplification
|
Aug 26, 2020 |
|
Webside Discussions Update - Pt 3 - Challenges and the Future for In Person Patient Care
|
Aug 19, 2020 |
|
Webside Discussions Update Pt 2 - Update on the Use of Telemedicine in Patient Care During the Pandemic
|
Aug 12, 2020 |
|
Webside Discussion Update Part 1- How Has the Coronavirus Pandemic Changed Cancer Management in Patient Care
|
Aug 05, 2020 |
|
Case Based Panel Discussion - What is the Recommended Treatment for Common EGFR Mutations
|
Jul 29, 2020 |
|
Case Based Panel Discussion - EGFR Mutation Treated with Tagrisso Progression While on Treatment, and What is the Role of Repeat Biopsy
|
Jul 22, 2020 |
|
Webside Manner - Remote Delivery of Medical Info and Care, Rapid Expansion of Telemedicine - Part 3
|
Jul 15, 2020 |
|
Webside Manner - Remote Delivery of Medical Info and Care, Rapid Expansion of Telemedicine - Part 2
|
Jul 08, 2020 |
|
Webside Manner - Remote Delivery of Medical Info and Care, Rapid Expansion of Telemedicine - Part 1
|
Jul 01, 2020 |
|
Case Based Panel Discussion - EGFR Mutation Oligoprogression in Brain and or Body vs Worsening Progression What are the Treatment Options?
|
Jun 24, 2020 |
|
Case Based Panel Discussion 3.1 EGFR Mutation - Chemotherapy and an EGFR Inhibitor Concurrently or Sequentially in Treatment Decisions?
|
Jun 24, 2020 |
|
Case Based Panel Discussion 2.2 Patient with Asymptomatic Brain Metastases -Focal Radiation Before Alk Inhibitor or Begin with ALK Inhibitor
|
Jun 10, 2020 |
|
Case Based Panel Discussion 2.1 Patient with Good Performance Status, Lung Adenocarcinoma, Metastatic Disease Adrenal Lesion
|
Jun 03, 2020 |
|
Case Based Panel Discussion 2.4 Initial Brain Mets Progression in Body After Success on ALK Inhibitor
|
May 27, 2020 |
|
Case Based Panel Discussion 2.5 Progression After ALK Inhibitors Is There a Role for Combination Therapies
|
May 20, 2020 |
|
Case Based Panel Discussion 2.3 Developing Resistance to Alk Inhibitors, Areas of Progression After Years of Success Treatment Approach
|
May 13, 2020 |
|
Case Based Panel Discussion 2.7 Clinical Significance of HER2 Mutation How Does a Positive HER2 Mutation Effect Treatment Decisions in NSCLC
|
May 06, 2020 |
|
Case Based Panel Discussion 2.6 ALK Positive and High PDL1 First Line Treatment for Potentially Competing Targets
|
Apr 29, 2020 |
|
Case Based Panel Discussion 2019 3. EGFR Uncommon Exon 20 Mutation - Suggested Treatments Targeted Therapy and Clinica Trial
|
Apr 22, 2020 |
|
Corona Virus and Covid 19 - Key Questions Part Four - Is the Standard Care Changing for Cancer Patients Because of the Pandemic?
|
Apr 19, 2020 |
|
Corona Virus and Covid 19 - Key Questions Part Three - What Preventive Measures are Trustworthy?
|
Apr 18, 2020 |
|
Corona Virus and Covid 19 - Key Questions Part Two - Do Cancer Patients Have a Higher Risk?
|
Apr 17, 2020 |
|
Corona Virus and Covid 19 - Key Questions Part One - Should Cancer Patients Get Tested?
|
Apr 16, 2020 |
|
Case Based Panel Discussion 2019 3.2 EGFR Mutation and the FLAURA Trial, Is There a Difference in Data Based on Demographics
|
Apr 15, 2020 |
|
Unresectable NSCLC - Does Checkmate 227's Suggestion of an Immunotherapy Combination of Yervoy and Opdivio Offer Another Treatment Option?
|
Apr 08, 2020 |
|
Unresectable NSCLC - Tumor Mutational Burden (TMB), the Value in Testing
|
Apr 01, 2020 |
|
Unresctable NSCLC - Concurrent Chemo & Radiation, Followed By Immunotherapy, Potential Pneumonitis Following Durvalumab (Imfinzi)
|
Mar 25, 2020 |
|
Unresectable NSCLC - For Varying Patient Scenarios, Fragile Patient, Attrition after 8-9 Months, What is the Best Schedule for Durvalumab
|
Mar 18, 2020 |
|
Unresectable NSCLC - Treatment Standard Concurrent Chemo & Rad Followed by Immunotherapy, Approach for Patients with PDL1 Score of 0
|
Mar 11, 2020 |
|
Unresectable NSCLC - Does Timing of Treatment Make a Difference in Response
|
Mar 04, 2020 |
|
Unresectable NSCLC In a Frail Patient with Competing Risks Is the Standard Treatment the Best Approach
|
Feb 26, 2020 |
|
Unresectable NSCLC - Should Molecular Tests Be Considered and Would Outcome Effect Treatment Decisions
|
Feb 19, 2020 |